Rapid response of spesolimab in biologics - failure patient with generalized pustular psoriasis flare.

Abstract

Generalized pustular psoriasis (GPP) is an intractable autoinflammatory skin disease characterized by diffused erythematous rashes and recurrent flares of pustular [1]. Effisayil™ 1 trial showed the IL-36 antibody spesolimab could bring fast clearance of pustules and lesions and excellent patient safety profile, which made it the first treatment option in the GPP flare approved by the Unit - ed States (US) [2, 3]. However, the efficacy and safety of spesolimab in Chinese population has not been clearly reported. We herein reported a Chinese case with a GPP flare who is heavily treated with other biologics but with poor response, and was successfully treated with spe - solimab. A 34-year-old female patient visited our department due to a 2-year history of GPP with a poor treatment ef - fect. She had a history of recurrent plaque-type psoriasis